Current Infectious Disease Reports

, Volume 5, Issue 2, pp 176–184

Update on the pathogenesis, diagnosis, and therapy of AIDs-related lymphoma

  • Richard F. Little
  • Wyndham H. Wilson

DOI: 10.1007/s11908-003-0055-1

Cite this article as:
Little, R.F. & Wilson, W.H. Curr Infect Dis Rep (2003) 5: 176. doi:10.1007/s11908-003-0055-1


AIDS-related non-Hodgkin’s lymphoma (ARL) is an opportunistic malignancy that foreshortens life more than any other commonly occurring HIV-associated cancer. Treatment strategies include low-dose chemotherapy, chemotherapy given with antiretroviral therapy, and infusional chemotherapy regimens. Rituximab, an anti-CD20 monoclonal antibody, has been found to be useful in non-HIV-associated lymphomas and is of interest in ARL as well. Since the advent of highly active antiretroviral therapy, the ARL incidence and survival has changed. This paper reviews the epidemiologic, biologic, and clinical features of ARL with the aim of presenting a cohesive overview of these elements.

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Richard F. Little
    • 1
  • Wyndham H. Wilson
  1. 1.HIV and AIDS Malignancy BranchCenter for Cancer Research, National Cancer Institute, National Institutes of HealthBethesdaUSA